CERo Therapeutics Holdings, Inc. Common Stock (CERO) — Financial Flexibility Index

Latest as of June 2026: -0.07x

CERo Therapeutics Holdings, Inc. Common Stock (CERO) has a Financial Flexibility Index of -0.07x as of June 2026. Free cash flow of $-2.33 Million (operating CF $-2.33 Million minus capex $0.00) represents 0% of total liabilities ($32.41 Million). Check tangible equity quality of CERo Therapeutics Holdings, Inc. Common to evaluate the tangible quality of the company's equity base.

Financial Flexibility Index

-0.07x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-2.33 Million
Operating CF − Capex

Total Liabilities

$32.41 Million
USD

Capital Expenditures

$0.00
USD

CERo Therapeutics Holdings, Inc. Common Stock Financial Flexibility Index (2021–2025)

Historical Financial Flexibility Index trend for CERo Therapeutics Holdings, Inc. Common Stock across 5 annual periods. For the full cash flow conversion analysis, see CERo Therapeutics Holdings, Inc. Common operating cash flow efficiency.

Annual Financial Flexibility Index for CERo Therapeutics Holdings, Inc. Common Stock (2021–2025)

Year-by-year free cash flow to debt coverage for CERo Therapeutics Holdings, Inc. Common Stock. Explore CERo Therapeutics Holdings, Inc. Common cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -1.77x $-16.08 Million $-16.08 Million $9.09 Million ▼ -147.6%
2024 -0.71x $-5.79 Million $-5.79 Million $8.10 Million ▼ -482.4%
2023 -0.12x $-5.79 Million $-5.79 Million $47.18 Million ▼ -1130.1%
2022 -0.01x $-398.01K $-1.09 Million $39.90 Million ▼ -9.1%
2021 -0.01x $-84.54K $-697.11K $9.25 Million —
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities